TTrialPathMatch Me to Trials
← Back to trials
RecruitingOvarian CancerPlatinum-sensitive Ovarian CancerPSOC

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Eligible age

18+ yrs

Accepts

Women

Locations

12 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved and used for ovarian cancer. Participants will receive either Rina-S monotherapy (by itself), Rina-S plus bevacizumab, bevacizumab (standard of care) by itself, or no treatment (only monitoring, also standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) for each participant will be different for every participant.

Sponsor: Genmab

Where it's recruiting

California

Sacramento

Connecticut

Hartford

Florida

Miami · New Port Richey · Sarasota

Maine

Scarborough

Maryland

Towson

Missouri

Columbia

Ohio

Centerville · Columbus

Pennsylvania

Hershey · Horsham

Texas

San Antonio

Virginia

Fairfax

Source: ClinicalTrials.gov · NCT07225270 · last updated 2026-11-16